Abstract: Methods for treating a movement disorder by intracranial administration to a human patient of a therapeutically effective amount of a neurotoxin, such as a botulinum toxin type A.
Abstract: The present invention provides a novel compound represented by the general formula I:
wherein R is H or COR3;
R1 is H, R2, phenyl, or COR3, wherein R2 is C1-C5 lower alkyl and R3 is R2 or phenyl;
Z is CH2 or O;
Y is OH, OCOR3 or ═O;
x is 0 or 1; and
X is C1-C5 n-alkyl, C3-C7 cycloalkyl, phenyl, furanyl, thienyl or substituted derivatives thereof, wherein the substituents maybe selected from the group consisting of C1-C5 alkyl, halogen, CF3, CN, NO2, NR42, CO2R4 and OR4 wherein R4 is hydrogen or C1-C5 alkyl and dotted lines represent the presence or absence of a double bond and wavy lines represent a cis or trans bond. These novel compounds are especially useful for treating elevated intraocular pressure (ocular hypertension) and glaucoma.
Type:
Grant
Filed:
May 8, 2001
Date of Patent:
October 23, 2001
Assignee:
Allergan Sales, Inc.
Inventors:
Robert M. Burk, Mark Holoboski, Mari F. Posner
Abstract: A biocompatible implant for continuous in vivo release of a neurotoxin over a treatment period extending from one month to five years. The implant can be made of casting a solution of a polymer, such as an ethyl vinyl acetate copolymer and the neurotoxin. The neurotoxin can be a botulinum toxin.
Abstract: The invention relates to 7-[5-hydroxy-2-(hydroxyhydrocarbyl or heteroatom-substituted hydroxy hydrocarbyl)-3-hydroxy-cyclopentyl(enyl)] heptanoic or heptenoic acids and derivatives of said acids, wherein one or more of said hydroxy groups are replaced by an ether group. The compounds of the present invention are potent ocular hypotensives, and are particularly suitable for the management of glaucoma.
Abstract: Methods and compositions for the treatment of lung disease, such as emphysema and/or bronchopulmonary dysplasia, in a mammal. Also disclosed are methods promoting the formation of alveolar septa and increasing the gas-exchange surface area of a mammalian lung, and for the prevention and/or treatment of alveolar destruction.
Type:
Grant
Filed:
April 13, 2000
Date of Patent:
October 16, 2001
Assignee:
Allergan Sales, Inc.
Inventors:
Gloria DeCarlo Massaro, Donald Massaro, Roshantha A. Chandraratna
Abstract: Compounds having Formula 3 wherein the symbols have the meaning defined in the specification are inhibitors of the cytochrome P450RAI (retinoic acid inducible) enzyme, and are used for treating diseases responsive to treatment by retinoids.
Type:
Grant
Filed:
August 29, 2000
Date of Patent:
October 16, 2001
Assignee:
Allergan Sales, Inc.
Inventors:
Jayasree Vasudevan, Alan T. Johnson, Roshantha A. Chandraratna
Abstract: A novel human cDNA, called TIG3 (Tazarotene Induced Gene 3), inducible by RAR-selective retinoids and structurally related to a known tumor suppressor gene. Methods of detecting the TIG3 polynucleotide.
Type:
Grant
Filed:
December 23, 1997
Date of Patent:
September 25, 2001
Assignee:
Allergan Sales, Inc.
Inventors:
Sunil Nagpal, Daniel DiSepio, Roshantha A. Chandraratna
Abstract: Compounds having Formula 7 wherein the symbols have the meaning defined in the specification are inhibitors of the cytochrome P450RAI (retinoic acid inducible) enzyme, and are used for treating diseases responsive to treatment by retinoids.
Type:
Grant
Filed:
August 29, 2000
Date of Patent:
September 18, 2001
Assignee:
Allergan Sales, Inc.
Inventors:
Jayasree Vasudevan, Alan T. Johnson, Dehua Huang, Roshantha A. Chandraratna
Abstract: The invention relates to the use of cyclopentane heptan(ene)oic acid, 2-thiocarbamoyloxy and carbamoyloxy as therapeutic agents e.g. as ocular hypotensives.
Abstract: The invention relates to a method for treating pruritus by administering a therapeutically effective amount of a PAF antagonist to a mammal afflicted with pruritus. The PAF antagonists may, for example, be selected from synthetic PAF analogues, natural products isolated from plants having PAF antagonist activity, and triazolobenzodiazepines. The PAF antagonists are preferably applied topically to the afflicted site but systemic such as oral, parenteral, nasal and intrarectal administration, is also possible.
Abstract: The application discloses methods of treating mammalian diseases characterized by undesirable angiogenesis by administering compounds including those having the general formulae
wherein A is a fused tropone having a general formula:
wherein X is selected from the group consisting of hydrogen, hydroxy, carboxy, halogen, nitro, C1 to C12 alkenyl, C1 to C12 alkyl, C1 to C12 alkoxy, SR, NR2, OSO3−, OSO2NR2, HNSO3−, NHSO2NR2, SSO3−, SSO2NR2, wherein R is hydrogen or a C1 to C6 alkyl and the 17-ester and keto derivatives thereof, in a dosage sufficient to inhibit cell mitosis. The application discloses novel compounds used in the method of the invention.
Abstract: Methods for treating otic disorders by local administration of a neurotoxin. A botulinum toxin can be administered to myoclonic middle ear muscles and to inner ear efferent and/or afferent nerves to alleviate otic disorders such as tinnitus, cochlear nerve dysfunction and Meniere's disease.
Abstract: A method for treating a pancreatic disorder by local administration of a therapeutic amount of a neurotoxin, such as a botulinum toxin, into or onto the body of the pancreas of a human patient, thereby treating a symptom of a pancreatic disorder.
Abstract: The present invention provides a method for treating acne vulgaris by serially applying a topical composition of azelaic acid and a topical composition of benzoyl peroxide. The present invention also provides topical compositions of a peroxide of benzoyl peroxide, and azelaic acid and its derivatives, such as azelaic acid, sodium salt or methylester which are useful for treating acne vulgaris and may be used to simultaneously apply benzoyl peroxide and azelaic acid.
Abstract: The invention relates to the use of omega chain modified prostaglandins as ocular hypotensive. The derivatives used in accordance with the invention are encompassed by the following structure formula I:
wherein the hatched segments represent &agr; bonds; the wavy segment represents an &agr; or &bgr; bond; dashed lines represent a double bond or a single bond; X is selected from the group consisting of —OR and N(R2); Y is=O or represents 2 hydrogen radicals, provided that Y represents 2 hydrogen radicals when X is OH; R is hydrogen or a lower alkyl radical having up to six carbon atoms; R1 is=O or hydroxy; m is 0, 2, 4 or 6, provided that m is not 4 when the wavy segment represents a &bgr; bond; n is 0, 2, 4 or 6; x and y are 0 or 1, provided that x is 1 when y is 0 and y is 1 when x is 0; or 9, 11 and/or 15 ester derivatives of said compound of formula I, e.g. a C1 to C6 alkyl ester derivative; or a pharmaceutically acceptable salt thereof.
Type:
Grant
Filed:
November 24, 1998
Date of Patent:
July 10, 2001
Assignee:
Allergan Sales, Inc.
Inventors:
Michael E. Garst, Michael B. Roof, Ming F. Chan, David F. Woodward, Robert M. Burk, Todd S. Gac, Steven W. Andrews
Abstract: Compounds having Formula 1 wherein the symbols have the meaning defined in the specification are inhibitors of the cytochrome P450RAI (retinoic acid inducible) enzyme, and are used for treating diseases responsive to treatment by retinoids.
Type:
Grant
Filed:
August 29, 2000
Date of Patent:
June 26, 2001
Assignee:
Allergan Sales, Inc.
Inventors:
Jayasree Vasudevan, Alan T. Johnson, Dehua Huang, Roshantha A. Chandraratna
Abstract: The present invention provides a novel compound represented by the general formula I;
wherein R is H or COR3;
R1 is H, R2, phenyl, or COR3, wherein R2 is C1-C5 lower alkyl and R3 is R2 or phenyl;
Z is CH2 or O;
Y is OH or OCOR3;
x is 0 or 1; and
X is C1-C5 n-alkyl, C3-C7 cycloalkyl, phenyl, furanyl, thienyl or substituted derivatives thereof, wherein the substituents maybe selected from the group consisting of C1-C5 alkyl, halogen, CF3, CN, NO2, NR42, CO2R4 and OR4 wherein R4 is hydrogen or C1-C5 alkyl and dotted lines represent the presence or absence of a double bond and wavy lines represent a cis or trans bond. These novel compounds are especially useful for treating elevated intraocular pressure (ocular hypertension) and glaucoma.
Type:
Grant
Filed:
September 20, 2000
Date of Patent:
June 19, 2001
Assignee:
Allergan Sales, Inc.
Inventors:
Robert M. Burk, Mark Holoboski, Mari F. Posner
Abstract: The present invention provides a method of providing neuroprotection to a mammal comprising administering to said mammal suffering from or at risk of suffering a noxious action on its nerve cells an effective amount of a compound of formula I to inhibit or prevent nerve cell injury or death
wherein the 2-imidazolin-2-ylamino group is in either the 5- or 6-position of the quinoxaline nucleus; x, y and z are in any of the remaining 5-, 6-, 7- or 8-positions and are selected from hydrogen, halogen, lower alkyl, lower alkoxy or trifluoromethyl; and R is an optional substituent in either the 2- or 3-position of the quinoxaline nucleus and may be hydrogen, lower alkyl or lower alkoxy, or pharmaceutically acceptable salts thereof and mixtures thereof. Such noxious action may result from ischemia, e.g. spinal ischemia.
Type:
Grant
Filed:
September 6, 2000
Date of Patent:
June 19, 2001
Assignee:
Allergan Sales, Inc.
Inventors:
Larry A. Wheeler, Elizabeth Woldemussie, Ronald K. Lai